Skip to content

Current Treatment Methods of Idiopathic Intracranial Hypertension

Evaluation of the Current Treatment Methods of Idiopathic Intracranial Hypertension

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06353412
Enrollment
64
Registered
2024-04-09
Start date
2024-06-01
Completion date
2026-03-09
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IIH - Idiopathic Intracranial Hypertension

Brief summary

Aim of the study : 1. to determine the response to each treatment plan. 2. to determine when to choose specific treatment method. 3. to determine complication of each type of treatment method

Detailed description

Idiopathic intracranial hypertension (IIH) is caused by an elevation of intracranial pressure (ICP). The condition mainly affects obese young women of childbearing age. In a recent study in the United Kingdom University of Kentucky urokinase, the estimated annual incidence was 4.7 % which represents a growth of 108% in 14 years, and parallels the growth of obesity prevalence . The combination of raised intracranial pressure, without hydrocephalus or mass lesion, normal cerebrospinal fluid (CSF) composition and where no underlying aetiology is found are accepted criteria for the diagnosis of IIH. The two most prominent symptoms of IIH are progressive visual deterioration and chronic headache, although additional symptoms including cranial nerve palsies, cognitive deficits, tinnitus and olfactory dysfunction are frequently also part of the clinical presentation. While the visual dysfunction is known to largely result from a pressure-induced papilledema, the origin of the IIH-related headache is less clear and therapeutic approaches are less investigated. The conventional treatment for IIH involves weight loss, steroids, diuretics, and serial lumbar punctures and surgical treatment. Surgical intervention should be conducted as soon as medical treatment fails. It is not acceptable to delay the intervention for patient with sever visual deterioration . Therefore surgery is indicated once visual loss continues despite optimum medical therapy . Medical treatment with acetazolamide and serial lumbar punctures represent the initial management, in such cases preserving surgery to non-responding cases and those who cannot tolerate medical treatment. Surgical treatment include lumboperitoneal shunt insertion , navigation guided ventriculo-peritoneal shunt ,endovascular stenting of sinuses in cases of sinus thrombosis and stenosis .

Interventions

PROCEDURELumbar puncture

Medical treatment Lumbar puncture Theco peritoneal shunt

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
16 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* patient has symptoms of increased intracranial pressure with :- * papilledema, * normal neurological examination,(except 6th nerve palsy), * elevated opening pressure( \>=25 cm) csf, * normal csf content

Exclusion criteria

* Any patient diagnosed with increased intracranial pressure due to: * sinus thrombosis or stenosis will be excluded from this study and .accordingly endovascular stenting as a method of treatment will be excluded from this study.

Design outcomes

Primary

MeasureTime frameDescription
Patient improvement regarding headache, visual symptoms1 yearDetermine the Severity of headache on scale from (0-10) ((0-4)\>mild, (5-7)\>moderate, (8-10)\>sever)
Patients improvement regarding fundus examination during regular visual assessment1 yearFundus examination grading (1-2-3-4)
Complication1 yearComplication of each treatment option

Secondary

MeasureTime frameDescription
Other1 yearCost of treatment and hospital stay (Relation between type of treatment and cost Of treatment, time of hospital stay) (type of treatment and number of days of hospital stay)

Contacts

Primary ContactMohamed AM Mansour, Master
Mohamed.15235787@med.aun.edu.eg01060685379

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026